滚动资讯
FierceBiotechGilead turns down chance to build on Assembly's phase 1-stage HBV antiviralFierceBiotechNovartis pays Synnovation $2B upfront for breast cancer program as rivals circleEndpoints NewsNovartis to pay $2B upfront to take next-gen PI3Kα inhibitor from SynnovationThermo Fisher欧盟批准赛默飞世尔数十亿美元收购Clario - marketscreener.comEndpoints NewsIdorsia looks for another CEO — again; Former Jazz exec makes a comebackEndpoints NewsGenentech culls muscle-preserving drug in genetic diseases, raising questions about obesity trialWatersFoguth Wealth Management LLC. Purchases New Stake in Waters Corporation $WAT - MarketBeatThermo FisherConfluence投资管理有限责任公司收购Thermo Fisher Scientific Inc. $TMO 11,841股股份 - MarketBeatIlluminaIllumina, Inc. $ILMN Shares Sold by CIBC Private Wealth Group LLC - MarketBeatThermo FisherArgent Capital Management LLC增持赛默飞世尔科技公司股份$TMO - MarketBeatAgilent安捷伦USCAP 2026病理学更新深化肿瘤诊断叙事 - simplywall.stAgilent友邦保险集团投资248万美元于安捷伦科技公司$A股 - MarketBeat
eLife 2026年1月23日

早期抗逆转录病毒治疗启动后24周，HIV特异性CD8+ T细胞增殖反应与后续病毒库减少相关

早期抗逆转录病毒治疗启动后24周，HIV特异性CD8+ T细胞增殖反应与后续病毒库减少相关

原文
暂时没有全文，请查看原始来源。

目录

59 全部